In summary, with respect to other inflammatory disorders, we demonstrated that antagonism of CCL5 showed therapeutic efficacy in models of contact skin reaction, both in a model of innate immunity (ICD) as well as in models of T-cell mediated skin pathology (CHS). Here, CCL5 is linked to impulse control disorder.